

# Survival Analysis

## Statistics in Medical Research Fall Series

Marcio Augusto Diniz, Ph.D.  
Biostatistics and Bioinformatics Research Center  
Cedars Sinai Medical Center

November 1, 2017

# Summary

- 1 Introduction
- 2 Graphical representation
- 3 Comparing survival curves
- 4 Regression models

# Example

## Relapse of autoimmune hepatitis

### Clinical trial

- Double-blind study;
- Groups: A (new treatment) and B (standard treatment);
- Aim: Comparing the percent of remission between groups along of three years.

# Example

## Relapse of autoimmune hepatitis

### Data

Treatment	Relapse	No Relapse	Drop out	Total
A	11	12	8	31
B	20	3	7	30

- $p$ : percentage of **success** (no relapse) considering ITT principle;
- $p_A = 38.7\%$  (12/31) and  $p_B = 10\%$  (3/30);
- $H_0 : p_A = p_B$  vs  $H_1 : p_A \neq p_B$ , p value = 0.015.

# Is time to remission important?

## Relapse of autoimmune hepatitis




Figure: Follow up of the first 5 patients by calendar time

# Is time to remission important?

## Relapse of autoimmune hepatitis




Figure: Follow up of the first 5 patients by trial time

# Is time to remission important?

## Relapse of autoimmune hepatitis




Figure: Hypothetical follow up of the first 5 patients until relapse by trial time

# Longitudinal studies

## Relapse of autoimmune hepatitis

### Definitions

- Start time;
- Length of follow-up;
- Clinical Endpoint (Death, Relapse);



# Longitudinal studies

## Relapse of autoimmune hepatitis

### Definitions

- Start time;
- Length of follow-up;
- Clinical Endpoint (Death, Relapse);

### Challenges

- Loss of patient follow-up.

# Longitudinal studies

## Relapse of autoimmune hepatitis

### What is censoring?

- It is any event that does not allow us to observe our endpoint;
- It should not be excluded.

# Longitudinal studies

## Relapse of autoimmune hepatitis

### What is censoring?

- It is any event that does not allow us to observe our endpoint;
- It should not be excluded.

### Assumptions

- It is not informative: censored patients would have the same probability of experiencing a event as non-censored patients.

# Summary

- 1 Introduction
- 2 Graphical representation**
- 3 Comparing survival curves
- 4 Regression models

# Kaplan-Meier curves

## Relapse of autoimmune hepatitis

- It is a methodology to estimate survival curves considering censoring;

Time	n at risk	n event	survival
0	61	0	1
36	60	1	$1 - 1/60$
56	58	1	$1 - 1/60 \times 1/58$

# Kaplan-Meier curves

Relapse of autoimmune hepatitis




Figure: Disease free survival combining treatments A and B

# Kaplan-Meier curves

## Relapse of autoimmune hepatitis

### Disease free survival at specific times

- 1 year: 56.48%, 95% CI: [44.94 ; 70.98]
- 2 years: 47.07%, 95% CI: [35.17 ; 63]

# Kaplan-Meier curves

## Relapse of autoimmune hepatitis

### Disease free survival at specific times

- 1 year: 56.48%, 95% CI: [44.94 ; 70.98]
- 2 years: 47.07%, 95% CI: [35.17 ; 63]

### Median disease free survival

- It represents the time such that 50% had experienced the event of interest; In this case, 22.57 months;
- It is usually calculated using the inverse of the Kaplan-Meier curves;
- It is not always possible to calculate.



# Kaplan-Meier curves

## Relapse of autoimmune hepatitis

### Disease free survival at specific times


- 1 year: 56.48%, 95% CI: [44.94 ; 70.98]
- 2 years: 47.07%, 95% CI: [35.17 ; 63]

### Mean disease free survival

- It is the area under the Kaplan-Meier curve;
- If there is censoring then the mean survival is not a good summary because the area under the curve is underestimated.

# Kaplan-Meier curves

## Relapse of autoimmune hepatitis



**Figure:** Disease free survival combining treatments A and B with median survival of 22.57 months and censoring rate of 24.5%.

# Summary

- 1 Introduction
- 2 Graphical representation
- 3 Comparing survival curves**
- 4 Regression models

# Kaplan-Meier curves

## Relapse of autoimmune hepatitis




Figure: Free disease survival by treatments

# Comparing two or more Kaplan-Meier curves

Relapse of autoimmune hepatitis

## Log-rank Test

- $H_0$ : there are **no** differences between the treatments;
- $H_1$ : there are differences between the treatments;
- If there are more than two curves, the test cannot indicate which curves are different from the others;
- It gives all the events the same weight.

# Summary

- 1 Introduction
- 2 Graphical representation
- 3 Comparing survival curves
- 4 Regression models**

# Regression model

## Relapse of autoimmune hepatitis

### Probabilistic model

- $T$ : time to event of interest;
- $T \sim$  distribution of probability;
- $\lambda(t)$  is the hazard function which represents the instantaneous rate of relapse:
  - ▶ It is not a probability;
  - ▶ It is a rate of relapse at time  $t$ .

# Hazard functions

## Relapse of autoimmune hepatitis





Figure: Hazard Function for Exponential distribution



# Hazard functions

## Relapse of autoimmune hepatitis



**Figure:** Increasing Hazard Function for Weibull distribution

# Hazard functions

## Relapse of autoimmune hepatitis




Figure: Decreasing Hazard Function for Weibull distribution

# Regression model

## Relapse of autoimmune hepatitis

### Proportional hazards model

- $T$ : time to event of interest;
- $T \sim$  distribution of probability;
- $\lambda(t)$  is written as proportional a base hazard function,

$$\lambda_A(t) = \lambda_B(t) \times \exp\{\beta_1 \times \text{Treatment A}\}$$

- It requires the definition of a distribution of probability to define  $\lambda_0(t)$ .

### Simple Cox proportional hazards model

- $T$ : time to event of interest;
- $T \sim$  distribution of probability;
- $\lambda(t)$  is written as proportional a base hazard function,

$$\lambda_A(t) = \lambda_B(t) \times \exp\{\beta_1 \times \text{Treatment A}\}$$

- It **does not** requires the definition of a distribution of probability to define  $\lambda_B(t)$ .
- If  $\beta_1 = 0$ , then  $\lambda_A(t) = \lambda_B(t)$ .

# Cox Regression

Relapse of autoimmune hepatitis

Coefficients	Estimate	Std. Error	z value	p value
(Treatment A) $\beta_1$	-0.92	0.37	2.45	0.014

Table: Fitted Simple Cox regression

What does this p value mean?

■  $H_0 : \beta_1 = 0$       $H_1 : \beta_1 \neq 0$ .

# Cox Regression

Relapse of autoimmune hepatitis

Coefficients	Estimate	Std. Error	z value	p value
(Treatment A) $\beta_1$	-0.92	0.37	2.45	0.014

Table: Fitted Simple Cox regression

## How to interpret the coefficients?

- We calculate the hazard ratio,

$$HR(\text{relapse}|A : B) = \exp\{\beta_1\} = 0.39$$

# Cox Regression

## Relapse of autoimmune hepatitis

Coefficients	Estimate	Std. Error	z value	p value
(Treatment A) $\beta_1$	-0.92	0.37	2.45	0.014

Table: Fitted Simple Cox regression

### How to interpret the coefficients?

- We calculate the hazard ratio,

$$HR(\text{relapse}|A : B) = \exp\{\beta_1\} = 0.39$$

- The treatment A has a hazard of relapse 60% ( $100 \times (1 - 0.39)$ ) lower than treatment A;

# Cox Regression

## Relapse of autoimmune hepatitis

Coefficients	Estimate	Std. Error	z value	p value
(Treatment A) $\beta_1$	-0.92	0.37	2.45	0.014

Table: Fitted Simple Cox regression

### How to interpret the coefficients?

- We calculate the hazard ratio,

$$HR(\text{relapse}|A : B) = \exp\{\beta_1\} = 0.39$$

- The treatment B has a hazard of relapse 2.53 ( $1/0.39$ ) (95% CI: 1.20 ; 5.31) times higher than the treatment A.



### Proportional hazards assumption

- It should always be verified to validate our inferences;
- If the Kaplan-Meier curves cross each other then there is evidence that the assumption is not verified;
- However, it should be verified by a statistical test using Schoenfeld residuals.

# Cox Regression

## Relapse of autoimmune hepatitis




Figure:  $H_0$ : proportional hazards vs  $H_1$ : non-proportional hazards,  $p$  value = 0.436

# Cox Regression

## Relapse of autoimmune hepatitis





Figure:  $H_0$ : proportional hazards vs  $H_1$ : non-proportional hazards,  $p$  value = 0.004

# Cox Regression

## Relapse of autoimmune hepatitis



**Figure:** Estimated survival curves by Kaplan-Meier

# Cox Regression

## Relapse of autoimmune hepatitis




Figure: Estimated survival curves by Kaplan-Meier




Figure: Estimated survival curves by Cox regression

### Multivariable Cox proportional hazards model

- $T$ : time to event of interest;
- $T \sim$  distribution of probability;
- $\lambda(t)$  is written as proportional a base hazard function,

$$\lambda_{A,Yes}(t) = \lambda_{B,No}(t) \times \exp\{\beta_1 \text{Treatment: A} + \beta_2 \text{Anti-SLA: Yes}\}$$

# Regression model

## Relapse of autoimmune hepatitis

### Multivariable Cox proportional hazards model

- $T$ : time to event of interest;
- $T \sim$  distribution of probability;
- $\lambda(t)$  is written as proportional a base hazard function,

$$\lambda_{A, \text{Yes}}(t) = \lambda_{B, \text{No}}(t) \times \exp\{\beta_1 \text{Treatment: A} + \beta_2 \text{Anti-SLA: Yes}\}$$

- $\beta_1 = 0$  implies to
  - ▶  $\lambda_{A, \text{Yes}}(t) = \lambda_{B, \text{Yes}}(t)$
  - ▶  $\lambda_{A, \text{No}}(t) = \lambda_{B, \text{No}}(t)$ ;

# Regression model

## Relapse of autoimmune hepatitis

### Multivariable Cox proportional hazards model

- $T$ : time to event of interest;
- $T \sim$  distribution of probability;
- $\lambda(t)$  is written as proportional a base hazard function,

$$\lambda_{A, \text{Yes}}(t) = \lambda_{B, \text{No}}(t) \times \exp\{\beta_1 \text{Treatment: A} + \beta_2 \text{Anti-SLA: Yes}\}$$

- $\beta_2 = 0$  implies to
  - ▶  $\lambda_{A, \text{Yes}}(t) = \lambda_{A, \text{No}}(t)$
  - ▶  $\lambda_{B, \text{Yes}}(t) = \lambda_{B, \text{No}}(t)$ .



# Cox Regression

Relapse of autoimmune hepatitis

Coefficients	Estimate	Std. Error	z value	p value
(Treatment A) $\beta_1$	-0.87	0.38	2.32	0.021
(Anti-SLA: Yes) $\beta_2$	1.11	0.38	2.89	0.003

Table: Fitted Multivariable Cox regression

What does these p values mean?

- $H_0 : \beta_1 = 0$       $H_1 : \beta_1 \neq 0$ .
- $H_0 : \beta_2 = 0$       $H_1 : \beta_2 \neq 0$ .

# Cox Regression

## Relapse of autoimmune hepatitis

Coefficients	Estimate	Std. Error	z value	p value
(Treatment A) $\beta_1$	-0.87	0.38	2.32	0.021
(Anti-SLA: Yes) $\beta_2$	1.11	0.38	2.89	0.003

Table: Fitted Multivariable Cox regression

### How to interpret the coefficients?

- We calculate the hazard ratio,

$$HR(\text{relapse}|A : B) = \exp\{\beta_1\} = 0.418$$

- The treatment B has a hazard of relapse 2.38 ( $1/0.418$ ) (95% CI: 1.14 ; 5.05) times higher than the treatment A.

# Regression model

## Relapse of autoimmune hepatitis

### Multivariable Cox proportional hazards model

- $T$ : time to event of interest;
- $T \sim$  distribution of probability;
- $\lambda(t)$  is written as proportional a base hazard function,

$$\lambda_{A, \text{Yes}}(t) = \lambda_{B, \text{No}}(t) \times \exp\{\beta_1 \text{Treatment: A} + \beta_2 \text{Anti-SLA: Yes} + \beta_3 \text{Treatment: A} \times \text{Anti-SLA: Yes}\}$$

### Multivariable Cox proportional hazards model

- $T$ : time to event of interest;
- $T \sim$  distribution of probability;
- $\lambda(t)$  is written as proportional a base hazard function,

$$\lambda_{A, \text{Yes}}(t) = \lambda_{B, \text{No}}(t) \times \exp\{\beta_1 \text{Treatment: A} + \beta_2 \text{Anti-SLA: Yes} + \beta_3 \text{Treatment: A} \times \text{Anti-SLA: Yes}\}$$

- $\beta_3 = 0$  implies to
  - ▶  $\lambda_{A, \text{Yes}}(t) - \lambda_{B, \text{Yes}}(t) = \lambda_{A, \text{No}}(t) - \lambda_{B, \text{No}}(t)$

### Multivariable Cox proportional hazards model

- $T$ : time to event of interest;
- $T \sim$  distribution of probability;
- $\lambda(t)$  is written as proportional a base hazard function,

$$\lambda_{A,Yes}(t) = \lambda_{B,No}(t) \times \exp\{\beta_1 \text{Treatment: A} + \beta_2 \text{Anti-SLA: Yes} + \beta_3 \text{Treatment: A} \times \text{Anti-SLA: Yes}\}$$

- $\beta_3 = 0$  and  $\beta_1 = 0$  implies to
  - ▶  $\lambda_{A,Yes}(t) = \lambda_{B,Yes}(t)$
  - ▶  $\lambda_{A,No}(t) = \lambda_{B,No}(t)$ ;

### Multivariable Cox proportional hazards model

- $T$ : time to event of interest;
- $T \sim$  distribution of probability;
- $\lambda(t)$  is written as proportional a base hazard function,

$$\lambda_{A, \text{Yes}}(t) = \lambda_{B, \text{No}}(t) \times \exp\{\beta_1 \text{Treatment: A} + \beta_2 \text{Anti-SLA: Yes} + \beta_3 \text{Treatment: A} \times \text{Anti-SLA: Yes}\}$$

- $\beta_3 = 0$  and  $\beta_2 = 0$  implies to
  - ▶  $\lambda_{A, \text{Yes}}(t) = \lambda_{A, \text{No}}(t)$
  - ▶  $\lambda_{B, \text{Yes}}(t) = \lambda_{B, \text{No}}(t)$ .

- British Medical Journal
- Clark, T. G., Bradburn, M. J., Love, S. B., & Altman, D. G. (2003). Survival analysis part I: basic concepts and first analyses. *British journal of cancer*, 89(2), 232.
- Bradburn, M. J., Clark, T. G., Love, S. B., & Altman, D. G. (2003). Survival analysis part II: multivariate data analysis - an introduction to concepts and methods. *British journal of cancer*, 89(3), 431.

- Bradburn, M. J., Clark, T. G., Love, S. B., & Altman, D. G. (2003). Survival analysis Part III: multivariate data analysis-choosing a model and assessing its adequacy and fit. *British journal of cancer*, 89(4), 605.
- Clark, T. G., Bradburn, M. J., Love, S. B., & Altman, D. G. (2003). Survival analysis part IV: further concepts and methods in survival analysis. *British journal of cancer*, 89(5), 781.
- Singh R, Mukhopadhyay K. Survival analysis in clinical trials: Basics and must know areas. *Perspectives in clinical research*. 2011 Oct 1;2(4):145.